MEET YOUR NEW AI CLINICAL ASSISTANT /// GET EARLY ACCESS
Tempus has recently announced the PMA approval for xT CDx, our solid tumor CDx and 648 gene panel.
In this webinar, you will hear how the Tempus platform can support development of new therapies by combining real-world data, next-generation sequencing, and artificial-intelligence to advance precision oncology. Our regulatory and scientific experts will provide an overview of the pathways for diagnostics and share best practices for biopharma and biotech sponsors to consider in clinical trial design and the development of companion diagnostics.
The Tempus TIME program provided Aadi access to a network of providers and patients to accelerate enrollment for its PRECISION 1 TSC1/TSC2 phase 2 clinical trial. Read on to learn how the TIME program decreased time to enroll with the just-in-time activation of ~10 business days.
Read more
Learn how AstraZeneca employs multimodal data to increase the probability of technical success of all Phase 3 oncology studies.
Watch replay
The TIME program enabled activation of a new clinical trial site within 4 business days for a PARPi study. Read on to learn how the patient was able to dose within 10 days of being identified as a match for the trial.
Read more